Healthcare
Exagen Inc.(XGN)
Live Price
Offline$4.54
+6.82% today
1Y Change
-34.86%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $70.00M
- Revenue Growth
- +19.7%
- EPS Growth
- -12.0%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Exagen Inc. (XGN) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $4.54 and down 34.9% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +19.7%, EPS growth of -12.0%, a dividend yield of 0.0%. What stands out right now is revenue +19.7%, EPS -12.0%, free cash flow -3.4% with operating margin -21.1% and ROIC -30.0%. Valuation is more restrained than many high-expectation growth names at price/sales 1.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines XGN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+19.7% vs +7.6% peer median
Operating Margin
Below sector median
-21.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on May 11, 2026 with an EPS surprise of +29.2% and a revenue surprise of +5.5%.
The operating picture looks softer than before
Revenue is at +19.7% and EPS is at -12.0%, with operating margin around -21.1%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 4, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -9.7% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | +29.2% | -6.8% | -12.3% | +8.3% |
2026 Mar 10, 2026 | +0.0% | -4.3% | -2.5% | -5.2% |
2025 Nov 4, 2025 | -46.1% | -4.1% | -14.4% | -32.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XGN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
XGN Max Drawdown
-77.84%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for XGN and SPY.
Company Overview
Exagen Inc.
NASDAQ Global Market
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
- Leadership
- John Aballi
- IPO Date
- Sep 19, 2019
- Employees
- 209
- Street Address
- 1261 Liberty Way
- Mailing
- Vista, CA, 92081
- Region
- Vista, CA, US
- Reporting Currency
- USD
- Investor Line
- 760 560 1501
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.1
- Price/Book
- 3.8
Growth
- Revenue
- +19.7%
- EPS
- -12.0%
- Free Cash Flow
- -3.4%
Profitability
- Gross Margin
- 58.3%
- Operating Margin
- -21.1%
- Net Margin
- -30.0%
- ROE
- -126.6%
- ROIC
- -30.0%
Balance Sheet
- Debt/Equity
- 1.59
- Current Ratio
- 3.45
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.